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Abstract
Background: Previous studies have demonstrates that, after nerve injury, extracellular signal-regulated protein
kinase (ERK) activation in the spinal cord-initially in neurons, then microglia, and finally astrocytes. In addition,
phosphorylation of ERK (p-ERK) contributes to nociceptive responses following inflammation and/or nerve injury.
However, the role of spinal cells and the ERK/MAPK pathway in cancer-induced bone pain (CIBP) remains poorly
understood. The present study analyzed activation of spinal cells and the ERK/MAPK pathway in a rat model of
bone cancer pain.
Results: A Sprague Dawley rat model of bone cancer pain was established and the model was evaluated by a
series of tests. Moreover, fluorocitrate (reversible glial metabolic inhibitor) and U0126 (a MEK inhibitor) was
administered intrathecally. Western blots and double immunofluorescence were used to detect the expression and
location of phosphorylation of ERK (p-ERK). Our studies on pain behavior show that the time between day 6 and
day 18 is a reasonable period ("time window” as the remaining stages) to investigate bone cancer pain
mechanisms and to research analgesic drugs. Double-labeling immunofluorescence revealed that p-ERK was
sequentially expressed in neurons, microglia, and astrocytes in the L4-5 superficial spinal cord following inoculation
of Walker 256 cells. Phosphorylation of ERK (p-ERK) and the transcription factor cAMP response element-binding
protein (p-CREB) increased in the spinal cord of CIBP rats, which was attenuated by intrathecal injection of
fluorocitrate or U0126.
Conclusions: The ERK inhibitors could have a useful role in CIBP management, because the same target is
expressed in various cells at different times.
Keywords: bone cancer pain, hyperalgesia, spinal cord, extracellular signal-regulated protein kinase (ERK), cAMP
response element-binding protein (CREB), rat
Background
Prevention and control of cancer-induced bone pain
(CIBP) is one of the most difficult tasks for pain man-
agement practitioners, although pain is very common in
bone cancer patients [1]. Currently, pharmacological
treatments for chronic pain are based on the under-
standing of mechanisms of drug action in non-cancer
pain syndromes. However, the treatments do not target
specific neurobiological changes in CIBP. To properly
evaluate the current therapies and development of novel
therapies, it is important to understand the underlying
mechanisms of CIBP.
Glial cells are classically viewed as central nervous sys-
tem (CNS) cells that passively provide a variety of impor-
tant metabolic and structural roles to support neurons
and do not actively participate in information processing.
However, recent studies have demonstrated the critical
importance of glial cells in a variety of biological func-
tions, including pain perception and modulation [2-5].
Astrocytes and microglia in the spinal cord participate in
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initiation and maintenance of persistent pain induced by
tissue inflammation and nerve injury. Peripheral nerve
injury induces neuropathic pain and phosphorylation of
mitogen-activated protein kinase (MAPK) family mem-
bers in dorsal root ganglia (DRG) and the dorsal horn.
Following nerve injury, phosphorylation of extracellular
signal-regulated protein kinase (ERK), an important
member of the MAPK family, increases sequentially in
neurons, microglia, and astrocytes of the dorsal horn.
Nerve injury-induced phosphorylation of ERK (p-ERK)
occurs early and is long-lasting, and in several animal
models of neuropathic pain, MEK inhibitors, which are
known to suppress ERK activation, have proven effective
in pain alleviation at various time points [6-8]. Spinal
nerve ligation (SNL) induces a particular temporal pat-
tern of ERK activation in the spinal cord-initially in neu-
rons, then microglia, and finally astrocytes [9]. ERK likely
contributes to neuropathic pain through various mechan-
isms in different cell types at different times. Therefore,
ERK/MAPK regulation is a promising therapeutic target
for treatment of neuropathic pain. However, the role
of spinal cells and the ERK/MAPK pathway in bone can-
cer pain remains poorly understood, although CIBP is
a unique state with features of neuropathy and
inflammation.
In a previous study from our laboratory, a rat model of
bone cancer pain [10-12] was established using female
Sprague Dawley (SD) rat carcinoma Walker 256 cells
according to a previously described method [13-17]. This
animal model was further utilized to demonstrate activa-
tion of three types of spinal cells and the ERK/MAPK
pathway in the spinal cord of CIBP rats and to assess the
role of the ERK/MAPK pathway in chronic bone cancer
pain.
Results
Radiological and histochemical analysis of tumor
development in the tibia
Bone destruction was monitored using radiological
(SPECT, X-ray and MRI) and histological methods
(Figure 1). Radiological analysis revealed decreased left
hind limb activity and minute bone trabecula defects
in the proximal epiphysis at 6 days after inoculation in
group V1 (in vitro Walker 256 cells) and group A1 (in
vivo Walker 256 cells) rats (Figure 1-B, b). Further
deterioration was detected at 12 days post-injection,
with full thickness unicortical bone loss, according to
radiological analysis (Figure 1-C, c), as well as bone
formation in the left proximal tibia, as detected by
SPECT (Figure 1-E). SPECT analysis provided better
contrast and more accurate detection and localization
of lesions compared with planar scintigraphy, which
demonstrated that SPECT scanning has value in the
diagnosis of bone metastatic cancer [18]. Rats from
group A1 and group V1 exhibited weight loss by day
15(data not shown). In addition, on day 18 after cell
injection, full-thickness, bicortical, bone loss, as well as
cortical destruction and soft tissue tumors [not
detected by X-ray (Figure 1-DV), but by MRI], was
observed by X-ray (Figure 1-D, d) and MRI (Figure 1-
G-K). At this time, because of the occurrence of soft
tissue tumors, it was assumed that extra-osseal tumor
growth was limited to the proximal epiphysis. How-
ever, in the following days, further bone erosion and
extra-osseal tumor dissemination were observed on
day 21 following inoculation (data not shown). There-
fore, it is presumed that day 6-18 post-inoculation is a
reasonable time window for evaluating anti-nociceptive
agents in this animal model. In addition, progressive
local bone destruction takes place at the proximal epi-
physis of the tibia during this time.
Histological examination revealed bone marrow spaces
infiltrated with malignant tumor on day 12 after inocu-
lation (Figure 1-F). Bone destruction was not observed
in the vehicle or sham group animals.
Mechanical allodynia
Following Walker 256 cell inoculation of the tibia
(groups V1 and A1), median paw withdrawal threshold
(PWT) of the inoculated hind paw progressively
decreased, and the contralateral hind paw remained
unchanged (data not shown). The overall difference
between the two hind paws was significant (P < 0.05,
data not shown). Dunn’s multiple comparisons test
revealed that median PWT from the inoculated paw was
significantly less than the contralateral paw or the con-
trol group between day 6 and 18 post-cell inoculation
(P < 0.01, Figure 2). These results suggested develop-
ment of mechanical allodynia in the inoculated hind
paw.
In this studies, Walker 256 cells, cultured in vitro and
in vivo, were utilized, and above methods and results
demonstrated that cells cultured in vivo and isolated
from ascitic fluid may be more user-friendly. Moreover,
at the beginning of this period (day 6), mechanical
hyperalgesia and allodynia were evident, which was ear-
lier or later than previously reported [day 10 to 14 [13],
and day 4 [14]], respectively. This difference was likely
due to differences in invasiveness and rat sexes of
MRMT-1 cells compared with Walker 256 cells.
Anti-nociceptive effect of intrathecal FC and U0126
The von Frey threshold in group FC significantly
increased at 4-12 h post-FC intrathecal injection com-
pared to groups FC vehicle sham and FC model sham
(P < 0.01, Figure 3A), with a peak anti-nociceptive effect
of 8 h. GFAP-positive astrocytes and OX-42-microglia
were atrophied and were more ramified in group FC
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Figure 1 Radiological and histochemical analysis of tumor development in the tibia. (A-D) To confirm bone destruction of the tibia by
tumor, rats were radiographed on 6 (Figure B and b), 12 (Figure C and c) and 18 days (Figure D and d) after carcinoma cell inoculation of the
ipsilateral hind limb. Arrows indicate structural destruction of the proximal cortical bone. In addition, for the control, bilateral hind limb of group
K1 rats on days 18 was showed in Figure A. (E) Whole body bone SPECT imaging at day 12 post-injection was showed in Figure E. SPECT
detected bone formation to be active in the left proximal tibia (see the arrows). (F) HE staining of the left tibia showed that bone marrow
spaces were infiltrated with malignant tumor (Cancer nest, see the arrow) on day 12 after Walker 256 cell inoculation. (G-K) On day 18 after
carcinoma cell inoculation, rats were also investigated with MRI (Magnetic Resonance Imaging) of the hind limbs (Figure G-K). After optimal
adjustment of contrast, axial T1-weighted imaging (A × T1, Figure G), axial T2-weighted imaging (A × T2, Figure H), coronal fat suppressed
sequence T2-weighted imaging (Cor × T2+, Figure I), axial enhanced T1-weighted imaging (A × T1+, Figure J), and coronal enhanced T1-
weighted imaging (Cor × T1+, Figure K) data were analyzed by visually identifying and encircling areas of abnormal signal intensity for each MR
section using a side to side comparison on the screen. Full thickness bicortical bone loss, cortical destruction, and soft tissue tumors were
observed obviously (Arrow).
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compared with groups FC vehicle sham and FC model
sham (P < 0.01, data not shown).
Three doses of U0126 (0.1, 1.0, and 10 μg) were com-
pared, revealing that 1 μg (group U0126-1.0) and 10 μg
(group U0126-10) U0126 significantly attenuated CIBP-
induced mechanical allodynia. However, 0.1 μg (group
U0126-0.1) U0126 had no effect. In addition, 1 and 10
μg intrathecal U0126 significantly reduced PWT com-
pared with the control group (P < 0.05, Figure 3B).
Although 1 μg U0126 attenuated mechanical allodynia
for 6 h after administration, 10 μg U0126 attenuated
mechanical allodynia for 9 h, which demonstrated that
intrathecal injection of 10 μg U0126 could relieve pain
for up to 9 h after administration.
CIBP-induced sustained activation of p-ERK and p-CREB in
the spinal cord
p-ERK (Figure 4A) and p-CREB (Figure 4B) were
assessed by Western blot analysis on day 3, 6, 9, 12, and
18 (n = 5/time group) after cell inoculation. Analysis
revealed low levels of p-ERK and p-CREB activation in
the L4-5 spinal dorsal horn at day 3, and that signifi-
cantly increased (P < 0.05) activation at other time
points (day 6, 9, 12, and 18) following CIBP.
At day 9, rats were sacrificed 6 h after U0126 (10 μg)
or vehicle (5% DMSO) intrathecal injection, or at 8 h
after FC or vehicle (0.3% 2 M HCl/PBS) injection. The
time points (6 and 8 h) were based on or pain-related
behavioral results of peak anti-nociceptive effects. Injec-
tion of U0126 or FC induced a rapid decrease in p-ERK
and p-CREB activation. From this time point on, a slow,
Figure 2 Mechanical allodynia (von Frey filaments). The 50%
paw withdrawal threshold (PWT) to a static mechanical stimulus
was assessed using von Frey filaments and the up-and-down
method. Rats received intra-tibial inoculations of two kinds of
Walker 256 cell suspension (1 × 105 cells/5 μl Hank’s solution)
(group V1 and group A1), heat-killed carcinoma cells in 5 μl Hank’s
solution (group K1), or 5 μl Hank’s solution only (group N1). PWT
was measured pre-surgery (Baseline, BL) and on days 3, 6, 9, 12, 15,
and 18 after cell inoculation (Figure 2). All data are expressed as
means ± SEM. **P < 0.01 vs. group N1. ## P < 0.01 vs. group K1.
Figure 3 Anti-nociceptive effect of intrathecal FC and U0126.
(A) The von Frey threshold in group FC was significantly increased
4-12 h post FC intrathecal injection compared with that in group FC
vehicle sham (Figure 3A). All data are expressed as means ± SEM. *P
< 0.05, ** P < 0.01 vs. group FC vehicle sham. ## P < 0.01 vs. group
FC model sham. (B) Three doses of U0126 (0.1, 1.0 and 10 μg) were
compared (Figure 3B). 1 μg (group U0126-1.0)and 10 μg (group
U0126-10) U0126 significantly attenuated the mechanical allodynia
induced by bone cancer pain, but 0.1 μg (group U0126-0.1) U0126
had no effect. 1 μg U0126 (group U0126-1.0) attenuated the
mechanical allodynia for 6 h after administration, while 10 μg U0126
(group U0126-10) attenuated the mechanical allodynia for 9 h after
treatment. This suggested that intrathecal injection of 10 μg U0126
may relieve pain, for up to 9 h after administration. *P < 0.05, ** P <
0.01 vs. group U0126 vehicle sham. ## P < 0.01 vs. group U0126
model sham.
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irregular decline of p-ERK and p-CREB expression
occurred (data not shown).
These results demonstrated decreased spinal ERK and
CREB activation following intrathecal administration of
U0126 or FC, which was consistent with previous anti-
nociceptive paradigms.
Sequential p-ERK activation in various cell types
At day 3 after carcinoma cell inoculation, p-ERK immu-
noreactive (IR) neurons were detected in the ipsilateral
spinal cord (Figure 6B-b, red), and the number of p-
ERK-positive cells was greater than in the contralateral
(data not shown) or control groups (Figure 6A-aa)
(including group with heat-killed cells, Group K2). The
p-ERK/NeuN double-labeled cells were located in the
superficial dorsal horn (laminae I-II) of the ipsilateral
L4-5 spinal cord. Neuronal p-ERK activation decreased
to a lower level (1-3 cells/section) in the deep (lamina
III-X) dorsal horn compared to controls on day 12.
Interestingly, On day 18 the neuronal p-ERK was little
activated again in the medial dorsal horn (laminae I-III)
although that was lower than the levels on day 3 (Figure
5). This could be due to late dorsal horn p-ERK activa-
tion, as discussed in the following.
Co-expression of p-ERK/OX-42 also occurred on day
3 and day 18 (Figure 5) following carcinoma cell inocu-
lation, although expression was less than p-ERK/NeuN
on day 3 and greater than the contralateral side (data
not shown) and in the control group (Figure 6A-aaa)
(including Group K2). These results were not consistent
with previous results [9], which demonstrated no co-
expression of p-ERK with either OX-42 or GFAP in the
early stage of model establishment (10 min for SNL
model). Further, results from the present study revealed
a relative peak for p-ERK-IR microglia at day 6 (Figure
5 and 6) after carcinoma cell inoculation. In addition,
Figure 4 Sustained activation of p-ERK and p-CREB in the
spinal cord induced by CIBP. The p-ERK (Figure 4A) and p-CREB
(Figure 4B) were tested through Western blots on day 3, 6, 9, 12, 18
(n = 5 for each time group) after cell inoculation. This analysis
revealed an activation of p-ERK and p-CREB in the L4-5 spinal dorsal
horn from day 3 although at a low level, and that significantly
increased (P < 0.05) at other time points (day 6, 9, 12, 18) examined
after CIBP. *P < 0.05, ** P < 0.01 vs. control (group N1), group FC
model sham, and group U0126 model sham. ΔP < 0.05, ΔΔP < 0.01
vs. group U0126 vehicle sham, and group U0126 model sham.
Figure 5 Percentage of double-labeling of p-ERK-IR cells. The
percentage of double-labeling of p-ERK-IR with NeuN, OX-42, or
GFAP-IR in the spinal dorsal horn (laminae I-III) on different days
(from day 3 to day 18) after carcinoma cells inoculation. About 200-
250 p-ERK-IR cells were counted in each condition. The percentage
of double-labeling = the number of double-labeled cells/number of
p-ERK-labeled cells. *P < 0.05, ** P < 0.01 vs. control (group N1).
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there was a substantial increase p-ERK expression in the
ipsilateral L4-5 spinal cord from day 3 to 9. This
sequential microglia p-ERK activation was widespread in
the dorsal and ventral horns. The majority of p-ERK-IR
cells in the L4-5 spinal cord expressed OX-42 (Figure
6C) at day 6 post-inoculation, with very few p-ERK-IR
cells expressing NeuN and GFAP. In addition, on day 9,
p-ERK was rarely detected in neurons, but remained
moderately present in microglia of the deep dorsal horn
(laminae III-V).
From day 9 onwards, co-expression of p-ERK/GFAP
slowly increased. GFAP-positive p-ERK expression was
detected primarily in the superficial dorsal (laminae I-II)
of the ipsilateral L4-5 spinal cord. On day 12, double-
labeling revealed predominant p-ERK expression in
GFAP-IR astrocytes (Figure 6D). Moreover, p-ERK was
expressed in some OX-42-IR cells in the deep dorsal
horn, although there was very little p-ERK/OX-42 co-
expression in the medial dorsal horn (laminae I-III).
Discussion
The present study successfully established a female bone
cancer pain model again, modified from that described by
Medhurst et al. [13-15]. Studies on pain behavior, includ-
ing mechanical allodynia (PWT) and spontaneous pain
(ambulatory score), from our laboratory demonstrated
that between day 6 and 18 is a reasonable period ("time
window”) to investigate bone cancer pain mechanisms and
the effect of analgesic drugs. In addition, after injection of
Walker 256 cells into the right tibia, left hind paw PWPT
(nociceptive hind paw withdrawal pressure threshold)
[data is presented in our previous study, [10]] also signifi-
cantly and progressively decreased from days 6 to 18. But
following injection of Walker 256 cells, the left hind paw
withdrawal latency (PWL) following a thermal nociceptive
stimulus only significantly decreased between days 3 and 6
compared with that of the contralateral hind paw and of
the hind paws of control, which remained at the pre-injec-
tion level (see Additional file 1). However, post-hoc means
comparisons revealed that Walker 256 cell inoculation of
the tibia induced no significant (P > 0.05) decrease of
PWL on days 9, 12, 15 and 18 after inoculation compared
with groups N1 and K1. This is different from previous
studies in CIBP [14]. But importantly, this is also observed
in the animals with the heat killed cells, indicating a non-
cancer effect at this time-point. We speculated that the
immune system may play a role in which. The reason for
this is unclear and is worthy of further study.
The MAPK family includes ERK, p38MAPK, and c-
Jun N-terminal kinase (JNK) [7]. Initiation of the ERK/
MAPK cascade involves activation of three kinases:
Ras®Raf®MEK®ERK/MAPK, and the ERK/MAPK
Figure 6 Sequent activation of p-ERK in different cell types respectively. On day 3 after carcinoma cell inoculation, moderate p-ERK
immunoreactive (IR) neurons (Figure 6B) were found in ipsilateral spinal cord which were much more than that of the control (Figure 6A-aa).
The p-ERK is colocalized with NeuN (Figure 6B-bb, green), and the double-labeling cells (Figure 6 B-bbb, yellow) were mainly located in the
superificial dorsal horn (laminae I-II) of the ipsilateral L4-5 spinal cord. The relative peak of p-ERK-IR microglia was on the day 6 after carcinoma
cell inoculation. The microglia p-ERK activation (Figure 6C-cccc, yellow) was widespread in the dorsal and ventral horns. Almost all p-ERK-IR cells
(Figure 6C-cc, red) in the L4-5 spinal cord expressed OX-42 (Figure 6C-ccc, green) which were much more than that of the control (Figure 6A-
aaa). Moreover, on day 12, double staining indicated that the p-ERK (Figure 6D-dd, red) was predominantly localized in GFAP-IR astrocytes
(Figure 6D-ddd, green).
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pathway is traditionally thought to play important roles
in cell proliferation and differentiation [19-22]. Recently,
ERK/MAPK activation was shown to contribute to noci-
ceptive responses in the dorsal horn and DRG following
inflammation and/or nerve injury [7,23]. Following
nerve injury [9], p-ERK levels sequentially increase in
neurons, microglia, and astrocytes of the dorsal horn. In
addition, nerve injury-induced p-ERK occurs early and
is long lasting. Moreover, previous studies [6,24,25]
reported that U0126 prevents early increases in CREB
phosphorylation in the superficial dorsal horn of chronic
constriction injury (CCI) or arthritic rats, indicating that
ERK/MAPK phosphorylation is likely an upstream sig-
naling event that regulates CREB activation in these
models [7]. In our present study, three doses of U0126
(0.1, 1.0, and 10 μg) were compared. Results demon-
strated that intrathecal injection of 1.0 μg (group
U0126-1.0) or 10 μg (group U0126-10) U0126 relieved
pain for up to 9 h after administration. The p-ERK and
p-CREB activation as detected in the L4-5 spinal dorsal
horn starting at day 3, although at a low level, which
significantly increased at other time points (day 6, 9, 12,
and 18) after CIBP. This change was attenuated by an
intrathecal injection of FC and U0126 on day 9 post-
inoculation, which indicated that spinal ERK/MAPK
pathway activation decreases with intrathecal adminis-
tration of drugs in existing anti-nociceptive paradigms.
ERK activation plays an important role in induction
and maintenance of neuropathic and inflammatory pain
through different cellular mechanisms in the spinal cord
[5]. A previous study [9] examined ERK activation pat-
tern in the spinal cord at different time points (2, 10,
and 21 days) after SNL, demonstrating sequential activa-
tion of ERK in the spinal cord after SNL. These results
support a role for microglia in the initiation phase and a
role for astrocytes in maintaining hypersensitivity. Dif-
ferent from SNL, CIBP is that the inflammation, tumor-
released products, and tumor-induced injury to primary
afferent neurons may simultaneously drive this chronic
pain state. However, the mechanism responsible for the
induction and maintenance of bone cancer pain is not
clearly understood. What is in some ways unique about
CIBP is that glial activation patterns in the spinal cord
are quite different. Inflammation, tumor-released pro-
ducts, and tumor-induced injury of primary afferent
neurons simultaneously drive the chronic pain state.
CIBP is rarely only neuropathic, inflammatory, ischemic,
or visceral, but is rather a combination of these. Clini-
cally, CIBP [1] exhibits the hallmarks of cancer pain: the
presence of disease with no pain at some sites and
severe pain at others. It remains unclear as to why some
areas of cancer growth and destruction induce pain,
while others do not, and why some are painful with no
apparent alteration in the level of damage or tumor
load.
In this study, double-label immunofluorescence
demonstrated that p-ERK was sequentially and respec-
tively expressed in neurons, microglia, and astrocytes of
the L4-L5 superficial spinal cord following inoculation
of Walker 256 cells. These results were consistent to
previously reported neuropathic pain models [9]. How-
ever, the microglia were also activated at day 3, with a
substantial increase from day 3 to 9, which was different
from previous CIBP results [5]. The reason for this dis-
crepancy remains unclear and is worthy of further
study. The difference of animals (rats vs mice) and carci-
noma cell lines (Walker256 cells vs NCTC cells) maybe
one of the reasons.
Pain is associated with altered gene expression in pri-
mary afferent neurons and second-order spinal cord neu-
rons [5]. Results from the present study revealed moderate
p-ERK expression in the ipsilateral spinal cord on day 3
after carcinoma cell inoculation. The vast majority of pri-
mary afferents, which make synaptic contacts with spinal
dorsal horn neurons, contain glutamate, which is released
by activity. Glutamate, substance P (SP), and calcitonin
gene-related peptide (CGRP) exert excitatory effects,
which lead to depolarization of spinal neurons. ERK acti-
vation may be an initial trigger of spinal neurons activa-
tion. In addition, reduced, but sustained, ERK activation is
present in dorsal horn neurons for several weeks, which
could play a role in maintaining gene expression.
Furthermore, microglial activation occurs following
injury to peripheral nerves [9] or CIBP. The present
results revealed a relative peak of p-ERK-expressing
microglia on day 6 after carcinoma cell inoculation. In
addition, there was a substantial increase in the ipsilateral
L4-5 spinal cord from day 3 to 9. Microglial-mediated
sensitization could be induced through release of nerve
sensitizing factors, such as brain-derived neurotrophic
factor (BDNF), interleukin (IL)-1b, tumor necrosis factor
(TNF)- a, nitric oxide (NO), and prostaglandins [5]. A
recent study from our laboratory [11] demonstrated a
critical role in CNS innate immunity for the microglial
Toll-like receptor 4 (TLR4) in induction and mainte-
nance of behavioral hypersensitivity in a rat model of
bone cancer pain. It is hypothesized that TLR4 could
serve as the main mediator in induction of bone cancer
pain. Further study of this early, specific, and innate
CNS/microglial response, and how it leads to sustained
glial/neuronal hypersensitivity, could lead to novel thera-
pies for prevention and treatment of bone cancer pain
syndromes.
Interestingly, on day 18, neuronal and microglia p-ERK
were slightly activated in the medial dorsal horn (laminae
I-III). It is possible that bone cortical destruction and soft
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tissue tumors could lead to increased primary afferent
input (peripheral sensitization), as well as hyperactivity of
spinal dorsal horn neurons (central sensitization).
Results demonstrated that p-ERK/GFAP co-expression
increased slightly starting at day 9, but was significantly
activated by day 12. Astrocytes are located very close to
neurons and are sensitive to alterations in neuronal
environments. Substances released by primary afferent
neurons (glutamate, SP, CGRP, ATP, and NO) and
microglia (BDNF, IL-1b, and TNF-a) can activate astro-
cytes, which supports a role for astrocytic p-ERK in the
maintenance of late-phase CIBP.
Moreover, in this article, the discrepancy change of
CREB-ERK1/2 phosphorylation and behavioural test was
also found on day 3. The inconsistent findings may be
due to the following reason: In this CIBP model, the
PWT (mechanical allodynia) was also reduced on day 3,
while there was no statistical difference between the nor-
mal control and cancer bone pain group. Importantly,
this is also observed in the animals with the heat killed
cells, indicating a non-cancer effect at this time-point.
We speculated that the immune system may play a role
in which. Moreover, radiographs showed no obvious
bone destruction in the tibia, indicating that tumor cells
did not metastasize at this time point. In addition, the
neuronal mechanisms that turn pain signals into beha-
vioral disorders are far from understood. It has been
reported by Zhuang [9] et al. that acute spinal nerve liga-
tion increases p-ERK level in the spinal dorsal horn, and
this activation has been found within 10 min while at this
time the mechanical allodynia should not occur. The rea-
son for this discrepancy change is unclear and is worthy
of further study.
Conclusion
The ERK inhibitors could have a useful role in CIBP
management, because the same target is expressed in
various cells at different times [7,9]. In addition, inhibi-
tion of a single target alters the function of neurons,
microglia, and astrocytes. Future studies should detail
the pathophysiological events that activate the ERK/
MAPK pathway and spinal cells to advance the under-
standing of the role of ERK phosphorylation and spinal
cells in mechanisms underlying bone cancer pain.
Methods
Animals
Female SD rats, weighing 180-200 g, were maintained
under controlled conditions (22-24°C, relative humidity
40-60%, 7:00 am-7:00 pm alternate light-dark cycles,
and free access to food and water). All experiments
were conducted in accordance with NIH guidelines and
the regulations of the Soochow University Committee
for the care and use of laboratory animals, and with the
approval of local Ethics Review Board [26].
Cell preparation
The Walker 256 mammary gland carcinoma cell line,
which are syngenic with the SD rat, were cultured in vitro
as previously described [10-12]. For injection, the cells
were collected and diluted to a final concentration of 2 ×
107 cells/ml and kept on ice until injected into rats.
For in vivo production, a total of 0.5 ml Walker 256
cells (2 × 107 cells/ml) were injected into the abdominal
cavity of SD rats. After 7-14 days, the ascites (approxi-
mately 50-150 ml) were collected. The cells were col-
lected by centrifugation for 3 min at 1200 rpm, and the
pellet was washed three times with 10 ml D-Hank’s
solution and re-centrifuged for 3 min at 1200 rpm.
Further, the cells were prepared as the above in vitro.
Two types of Walker 256 cell preparations, in vitro
and in vivo, were injected into the tibial medullary cavity
via the intercondylar eminence. 10 μl of cells were
injected (approximately 1 × 105 cells/10 μl Hank’s solu-
tion) into each rat. For the sham group, Walker 256
cells were prepared to the same final concentrations and
boiled for 20 min.
Surgical procedures
The surgery (n = 8/group) was committed as described
previously [10-12]. All rats were anesthetized with
sodium pentobarbital (45 mg/kg, i.p.). During the proce-
dures, the Walker 256 cells (1 × 105 cells/10 μl Hank’s
solution) were then cultured in vitro (group V1), in asci-
tic fluid in vivo (group A1), heat-killed carcinoma cells
in 10 μl Hank’s solution (group K1), or 10 μl Hank’s
solution only (group N1) and were slowly injected into
the cavity of the left tibia. Finally, all animals were
allowed to recover from the inoculation surgery for 3
days prior to any experimentation.
Five days before intra-tibial injection of Walker256
cells, according to the modification of a method
described previously [10-12], an intrathecal catheter (PE-
10 tube) was inserted through the gap between the L3
and L4 vertebrae. The volume of dead space of the
intrathecal catheter was 10 μl. To avoid occlusion of the
catheter, 10 μl of normal saline was injected via a cathe-
ter on alternate days until the end of the experiment. The
cannulated rats were allowed to recover for 3-4 days.
Radiological bone examination
To determine tibial destruction from the inoculated
tumor, rats were radiographed at 6, 12, and 18 days fol-
lowing carcinoma cell inoculation. Rats were placed on
clear plexiglass and were exposed to an X-ray source
under sodium pentobarbital anesthesia (45 mg/kg, i.p.).
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Using a Kodak Digital Radiographer System (Kodak,
USA), tibial radiographs were taken (40 KVP, 2 ma)
from hind limbs of groups V1, A1, K1, and N1 (n =
3/group).
In addition, at 12 days after carcinoma cell inocula-
tion, single photo emission-computed tomography
(SPECT) was used to determine alterations in local bone
metabolism. The rats were anesthetized and placed in a
prone position on the surgery table. A total of 0.2 ml
99Tcm-MDP (methylene diphosphonate, 5 mCi, or 185
MBq per injection) was injected into the tail vein, and
dynamic data and images of hind limbs were collected,
during blood flow perfusion phase and after 3 hours.
Images and 5-minute dynamic data were collected dur-
ing the bone phase.
Magnetic Resonance Imaging (MRI) was used to analyze
hind limbs at 18 days after carcinoma cell inoculation (n =
3 rats/group). Following complete anesthesia induction
with sodium pentobarbital (45 mg/kg, i.p.), gadolinium-
DPTA [0.5 ml (235 mg), Gd-DTPA] was injected into the
tail vein at 15 minutes after MRI. Following optimal
adjustment of contrast, axial T1-weighted imaging (A ×
T1, TR:500.00 ms/TE: 12 ms/5 mm/Fov 12 cm/256 × 256/
2), axial T2-weighted imaging (A × T2, TR:4221.00 ms/
TE:106.2 ms/5 mm/Fov 12 cm/512 × 512/2), coronal fat-
suppressed sequence T2-weighted imaging (Cor × T2+,
TR:4600.00 ms/TE:110 ms/5 mm/Fov 12 cm/256 × 256/
2), axial enhanced T1-weighted imaging (A × T1+,
TR:500.00 ms/TE:12 ms/5 mm/Fov 12 cm/256 × 256/2),
and coronal-enhanced T1-weighted imaging (Cor × T1+,
TR:331.00 ms/TE:17.9 ms/5 mm/Fov 12 cm/256 × 256/2)
data were analyzed by visual identification and encircling
of areas of abnormal signal intensity for each MR section
using side-to-side comparison on the screen.
Histochemical staining
At 12 days after carcinoma cell inoculation and demi-
neralization in EDTA (10%) for 2-3 weeks, the tibiae
were embedded in paraffin and 5-μm thick sections
were cut using a microtome. The sections were stained
with Harris’ hematoxylin and eosin (HE) to verify cancer
cell infiltration and bone destruction (n = 4/group).
Drugs
Intrathecal injection (i.t.) of all drugs was accomplished
via lumbar puncture at level L4-5 under brief halothane
anesthesia (n = 10/group).
Fluorocitrate (FC, 1 nmol in 10 μl; Sigma), a reversible
glial metabolic inhibitor, inhibits aconitase, a Kreb’s
cycle enzyme expressed in glia, but not neurons [27].
FC was initially dissolved in 2 M HCl and then diluted
in 10 mM phosphate-buffered saline (PBS, pH 6.0). At 9
days after carcinoma cell inoculation, rats received an
intrathecal (i.t.) injection of FC (1 nmol, group FC) or
vehicle (0.3% 2 M HCl in PBS, pH 6.0, group FC vehicle
sham). Hind paw withdrawal threshold (PWT) for
mechanical stimulation was measured using a von Frey
filament at 1 h before FC administration (baseline), and
at 1, 2, 4, 6, 8, 10, 12, and 24 h after FC administration,
as well as 3, 6, 9, 12, 15, and 18 d after carcinoma cell
inoculation.
U0126 (a MEK inhibitor) was dissolved in 5% DMSO
and injected i.t. at 0.1 μg/10 μl (group U0126-0.1), 1.0
μg/10 μl (group U0126-1.0), and 10 μg/10 μl (group
U0126-10) on day 9 after carcinoma cell inoculation.
PWT was measured 1 h prior to U0126 administration
(baseline) and at 1, 3, 6, 9, 12, and 24 h after U0126
administration and at 3, 6, 9, 12, 15, and 18 d after car-
cinoma cell inoculation.
The FC and U0126 doses were based on preliminary
experiments (data not shown) and on previous studies
of inflammatory pain [28,29]. FC vehicle (0.3% 2 M HCl
in PBS, pH 6.0, group FC vehicle sham) or U0126 vehi-
cle (5% DMSO, group U0126 vehicle sham) was used as
a positive control, and 10 μl was injected i.t. at the same
times as FC or U0126 administration, as described
above. For the negative controls, 10 μl of FC (1 nmol in
10 μl, group FC model sham), or U0126 (10 μg/10 μl,
group U0126 model sham) were injected i.t. at the same
time as FC or U0126, as described above, following
inoculation of 10 μl Hank’s solution.
Mechanical allodynia through the use of von Frey
filaments
The 50% paw withdrawal threshold (PWT) to a static
mechanical stimulus was assessed using von Frey fila-
ments and the up-and-down method [30] which just
like we described previously [10,11]. The PWT was
measured pre-surgery (baseline, BL) and on days 3, 6, 9,
12, 15, and 18 after cell inoculation. The behavioral test
investigator was blinded to group assignments.
Immunohistochemistry
At 2 h after behavioral testing, the rats (n = 5/group)
from the N2 group (normal control rats), K2 group
(heat-killed carcinoma cells in 10 μl Hank’s solution), A2
(d3) group (sacrificed 3 days after inoculation of in vitro
Walker 256 cells), as well as A2(d6) group, A2(d9) group,
A2(d12) group, and A2(d18) group (sacrificed at day
6,9,12 and 18 respectively) were deeply anesthetized with
sodium pentobarbital (60 mg/kg i.p.). The histochemistry
of double immunofluorescence was performed 10-μm
thick, free-floating, L4-5 spinal cord sections as we pre-
viously described [28]. Mouse anti-neuronal nuclei
(NeuN) Alexa Fluor 488-conjugated monoclonal anti-
body (neuronal marker, 1:100, Chemicon/Millipore,
USA.) was used to label the neurons. Mouse anti-rat
OX-42 FITC-conjugated monoclonal antibody (1:10;
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Chemicon/Millipore, USA) was used to label CR3/CD11b
on activated microglia. Mouse anti-glial fibrillary acidic
protein (GFAP) Alexa Fluor 488-conjugated monoclonal
antibody (1:1000; Chemicon/Millipore, USA) was used to
label astrocytes. Anti-phosphorylated ERK (p-ERK,
1:2000; Santa Cruz, USA) was used to detect ERK activa-
tion. For double immunolabeling of p-ERK/NeuN,
p-ERK/OX-42, and p-ERK/GFAP, sections were incu-
bated in a mixture of antibodies. The sections were
rinsed and incubated in Alexa Fluor 594-conjugated sec-
ondary antibodies for 3 h (Molecular Probes, 1:200,
USA). Digital images were captured from 5 randomly
selected sections per animal, and 3 squares (250 ×
250 μm) per section were chosen. The stained sections
were analyzed using laser-scanning confocal microscopy
(Leica, Germany) and fluorescent microscopy (Olympus
CKX61, Japan). In addition, for the quantification, the
numbers (NUM) of GFAP, OX-42, and p-ERK immuno-
fluorescence-stained single-or double-labeled positive
cells in each image was counted with a computer-assisted
image analyzer (Image Pro-plus 6.0, Kodak, USA). All
measurements were performed by an author who was
blind with respect to treatments. The results were aver-
aged for each individual rat. To test immunohistochemis-
try specificity, primary or secondary antibodies were
omitted. Under these conditions, staining corresponding
to the second primary antibody was not observed.
Western blot analysis
Animals (n = 5/time group) were sacrificed rapidly in a
CO2 chamber. The L4-5 dorsal horns were quickly
removed by hydraulic extrusion with saline. The lumbar
cord was immediately frozen and maintained at -80°C
[9]. Western blot analysis of the p-ERK and p-CREB
was performed as previously described [11,12]. Among
this, quivalent amounts of protein (30 μg) were used
and a rat monoclonal antibody against total ERK or
CREB antibody (1:1000; Santa Cruz) was used as the
loading control. Western blot analysis was performed as
previously described [31]. Scanning densitometry was
used for semi-quantitative analysis with a computer-
assisted image analyzer (Gel Pro Analyzer, USA).
The p-ERK and p-CREB were measured on day 3, 6, 9,
12, and 18 following cell inoculation (n = 5/time group).
In addition, on day 9, rats were sacrificed 6 h after
U0126 (10 μg) or vehicle (5% DMSO) intrathecal injec-
tion, or at 8 h after FC or vehicle (0.3% 2 M HCl/PBS)
injection. The effective dose of U0126 (10 μg) and time
point (6 and 8 h each) was based on pain-related beha-
vioral experiments (see results from anti-nociceptive
effect of intrathecal U0126 and FC). For the control,
U0126/FC vehicle sham, and U0126/FC model sham
groups (n = 4/group) were sacrificed, and p-ERK and p-
CREB were measured at 6 h or 8 h, respectively.
Statistical analyses
Statistical analysis was performed using software SPSS
16.0 (SPSS Inc). All data are expressed as mean ± stan-
dard error of mean (SEM). Data from the immunohisto-
chemical analysis and Western blots studies were
accomplished using a one-way analysis of variance
(ANOVA) followed by post hoc Dunnett testing. Data
from the nociceptive tests were analyzed using ANOVA
followed by Bonferroni testing for tactile allodynia test-
ing. A value of P < 0.05 was considered significant. The
individual investigators responsible for behavioral testing
and immunohistochemical quantification were blinded
to the experimental situation.
Additional material
Additional file 1: paw withdrawal latency (PWL) test following a
thermal nociceptive stimulus. Before Walker 256 cell injection, the
overall mean baseline paw withdrawal latency (PWL) to noxious heat
stimuli (using a previously described method [Hargreaves, et al. Pain 32,
77-88.] [Lina W, et al. Brain Res 2006; 1120:46-53.]) was similar in all
groups of rats and there was no significant difference in PWL between
left and right hind paws. Following injection of Walker 256 cells cultured
in vitro (group V1) and in vivo (group A1) into the left tibia, the left hind
paw PWL significantly and progressively decreased between days 3 and
6 compared with that of the contralateral hind paw and of the hind
paws of groups N1 and K1, which remained at the pre-injection level
(* P < 0.05 ** P < 0.05 vs Group N1; # P < 0.05 vs Group K1, see
Additional file 1). However, post-hoc means comparisons revealed that
Walker 256 cell inoculation of the tibia induced no significant (P > 0.05)
decrease of PWL on days 9, 12, 15 and 18 after inoculation compared
with groups N1 and K1.
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